{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:21:41Z","timestamp":1760239301292,"version":"build-2065373602"},"reference-count":58,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The multiple myeloma (MM) non transplant eligible (NTE) population is growing in line with the aging of the population in Western countries. Historically, this population has been known for having a greater risk of treatment related toxicity, and therefore drug development was slow and rather oriented towards the improvement of safety profile than the optimization of disease control. However, NTE MM patients, at least for the fit\/non frail patients in recent years, seemed to have benefited more from a less palliative care to improve the depth of response and then prolong survival. NTE MM being a quite heterogeneous population, there are still a number of groups of patients that are in need of more efficient therapy, avoiding unnecessary toxicity, particularly for the frail patients. The use of triplet regimen with a melphalan-prednisone (MP) backbone has long been the standard of care for NTE MM, often dedicated to non-frail patients. New standards of care, triplet, and even quadruplet combinations, are emerging on the basis of the MP backbone but also on the more recently approved lenalidomide-dexamethasone (Rd) backbone. These developments were largely possible in line with the development of antibody-based immunotherapies (IT) in MM. The objective to improve outcomes with an acceptable safety profile will see other key therapeutic developments such as the dropping of dexamethasone early in the disease course or various attempts to allow permanent treatment discontinuation with a prolonged disease control. In that context, it is possible that immunomonitoring, minimal residual disease (MRD), and genomic risk-adaptation will become key elements of the treatment decisions on triplet-based regimens.<\/jats:p>","DOI":"10.3390\/jcm9113554","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:37Z","timestamp":1604534437000},"page":"3554","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients"],"prefix":"10.3390","volume":"9","author":[{"given":"H\u00e9l\u00e8ne","family":"Gardeney","sequence":"first","affiliation":[{"name":"Service d\u2019Hematologie et Therapie Cellulaire, and Inserm CIC U1402, 86000 Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Bobin","sequence":"additional","affiliation":[{"name":"Service d\u2019Hematologie et Therapie Cellulaire, and Inserm CIC U1402, 86000 Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Gruchet","sequence":"additional","affiliation":[{"name":"Service d\u2019Hematologie et Therapie Cellulaire, and Inserm CIC U1402, 86000 Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Sabirou","sequence":"additional","affiliation":[{"name":"Service d\u2019Hematologie et Therapie Cellulaire, and Inserm CIC U1402, 86000 Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"L\u00e9vy","sequence":"additional","affiliation":[{"name":"Service d\u2019Hematologie et Therapie Cellulaire, and Inserm CIC U1402, 86000 Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laly","family":"Nsiala","sequence":"additional","affiliation":[{"name":"Service d\u2019Hematologie et Therapie Cellulaire, and Inserm CIC U1402, 86000 Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cailly","sequence":"additional","affiliation":[{"name":"Service d\u2019Hematologie et Therapie Cellulaire, and Inserm CIC U1402, 86000 Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4093-6463","authenticated-orcid":false,"given":"C\u00e9cile","family":"Tomowiak","sequence":"additional","affiliation":[{"name":"Service d\u2019Hematologie et Therapie Cellulaire, and Inserm CIC U1402, 86000 Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Torregrosa","sequence":"additional","affiliation":[{"name":"Service d\u2019Hematologie et Therapie Cellulaire, and Inserm CIC U1402, 86000 Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Moya","sequence":"additional","affiliation":[{"name":"Service d\u2019Hematologie et Therapie Cellulaire, and Inserm CIC U1402, 86000 Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie et de Th\u00e9rapie Cellulaire, CHU de Bordeaux, 33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"Service d\u2019Hematologie et Therapie Cellulaire, and Inserm CIC U1402, 86000 Poitiers, France"},{"name":"Service d\u2019H\u00e9matologie et Th\u00e9rapie Cellulaire, Universite de Medecine et Pharmacie, 33000 Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Guidez","sequence":"additional","affiliation":[{"name":"Service d\u2019Hematologie et Therapie Cellulaire, and Inserm CIC U1402, 86000 Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","article-title":"Elderly patients with multiple myeloma","volume":"29","author":"Zweegman","year":"2017","journal-title":"Curr. Opin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO.2012.46.2598","article-title":"Chromosomal Abnormalities Are Major Prognostic Factors in Elderly Patients with Multiple Myeloma: The Intergroupe Francophone du My\u00e9lome Experience","volume":"31","author":"Hulin","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): A development and validation study","volume":"6","author":"Cook","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1111\/bjh.16194","article-title":"A novel Haemato-oncology Frailty (HOF) score tool predicts survival in over 80s with Multiple Myeloma","volume":"187","author":"Hinton","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: Analysis of 1175 patients","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/bmt.2016.174","article-title":"Autologous stem cell transplant for multiple myeloma patients 70 years or older","volume":"51","author":"Muchtar","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02976.x","article-title":"Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years","volume":"114","author":"Badros","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00277-018-3528-x","article-title":"Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma","volume":"98","author":"Marini","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.bbmt.2014.07.013","article-title":"Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation","volume":"20","author":"Sharma","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/bmt.2014.255","article-title":"Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: Increased use and improved outcomes in elderly patients in recent years","volume":"50","author":"Auner","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): A randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1182\/blood.V118.21.476.476","article-title":"Continued Overall Survival Benefit After 5 Years\u2019 Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial","volume":"118","author":"Miguel","year":"2011","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","article-title":"Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"133","author":"Facon","year":"2019","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1002\/ajh.25327","article-title":"Carfilzomib weekly 20\/56 mg\/m2, lenalidomide and dexamethasone for early relapsed refractory multiple myeloma","volume":"94","author":"Richez","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1182\/blood-2015-02-626168","article-title":"Phase 1\/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1158\/1078-0432.CCR-18-3642","article-title":"Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial","volume":"25","author":"Leleu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/10428194.2016.1177772","article-title":"A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation","volume":"58","author":"Weisel","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3324\/haematol.2019.220657","article-title":"First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: A pooled analysis of two randomized trials","volume":"105","author":"LaRocca","year":"2019","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"Laubach","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/14656566.2019.1577822","article-title":"The pharmacologic management of multiple myeloma in older adults","volume":"20","author":"Dempsey","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/s41375-019-0384-1","article-title":"Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: Long-term follow-up including ixazomib maintenance","volume":"33","author":"Kumar","year":"2019","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjh.15394","article-title":"Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma","volume":"182","author":"Richardson","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_33","unstructured":"(2020, April 28). Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial. Available online: https:\/\/www.takeda.com\/newsroom\/newsreleases\/2020\/takeda-provides-update-on-tourmaline-mm2-phase-3-trial\/."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-018-0583-7","article-title":"Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study","volume":"11","author":"Dimopoulos","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2018-99-112093","article-title":"Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation vs. KRd 12 Cycles vs. Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)","volume":"132","author":"Gay","year":"2018","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"LBA3","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA3","article-title":"Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial","volume":"38","author":"Kumar","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2019.37.15_suppl.8005","article-title":"Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA","volume":"37","author":"Mateos","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.clml.2015.12.007","article-title":"Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study","volume":"16","author":"Berdeja","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): A randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood-2018-99-114029","article-title":"Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial","volume":"132","author":"Sonneveld","year":"2018","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: Elotuzumab plus bortezomib\/dexamethasone vs. bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"key":"ref_52","unstructured":"Moreau, P. Inc MG. Isatuximab Plus Carfilzomib and Dexamethasone vs. Carfilzomib and Dexamethasone in Relapsed\/Refractory Multiple Myeloma (IKEMA): Interim Analysis of a Phase 3, Randomized, Open-Label Study. EHA25 Virtual Congress. Abstract LB2603."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): A multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8527","DOI":"10.1200\/JCO.2020.38.15_suppl.8527","article-title":"Ixazomib vs. placebo maintenance for newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT): The phase III TOURMALINE-MM4 trial","volume":"38","author":"Dimopoulos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1038\/bcj.2016.68","article-title":"Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: Long-term follow-up","volume":"6","author":"Biran","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-Arm, Randomised, Open-Label, Phase 2 Study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: An overview and consensus from the European Myeloma Network (EMN)","volume":"32","author":"LaRocca","year":"2018","journal-title":"Leukemia"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3554\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:29:21Z","timestamp":1760178561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":58,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["jcm9113554"],"URL":"https:\/\/doi.org\/10.3390\/jcm9113554","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2020,11,4]]}}}